Stock Price Movement Update, Recognitions, and Financial Results - Research Report on Ariad Pharmaceuticals, Quintiles, Molina Healthcare, Exelixis, and Masimo
NEW YORK, November 4, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Quintiles Transnational Holdings Inc. (NYSE: Q), Molina Healthcare, Inc. (NYSE: MOH), Exelixis, Inc. (NASDAQ: EXEL), and Masimo Corporation (NASDAQ: MASI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Ariad Pharmaceuticals Inc. Research Report
On October 30, 2013, Ariad Pharmaceuticals Inc.'s (Ariad Pharmaceuticals) stock rose 4.49%, ending the day at $3.96. Over the previous three trading sessions, shares of Ariad Pharmaceuticals gained 11.24%, compared to the Nasdaq Composite, which declined 0.32% during the same period. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/161c_ARIA]
Quintiles Transnational Holdings Inc. Research Report
On October 22, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced that after receiving nine individual Great Place to Work awards in 2013, the Company was again recognized as one of the World's Best Multinational Workplaces by Great Place to Work, ranking 18th on the 2013 list. According to Quintiles, the ranking is the world's largest annual study of workplace excellence and identifies the top-25 best multinationals in terms of workplace culture, and Quintiles has been named to the Best Multinational Workplace list in each of the ranking's three years of existence. Quintiles' Chief Administrative Officer, Mike Mortimer, said, "We are honored to be among the top-25 multinational workplaces again this year. As a service provider, the value we bring to our biopharma customers comes directly from our 27,000-plus employees around the world. Creating and maintaining a positive working environment which the best and brightest seek out is a key component of Quintiles' success." The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9f5c_Q]
Molina Healthcare, Inc. Research Report
On October 30, 2013, Molina Healthcare, Inc. (Molina Healthcare) reported its Q3 2013 financial results. The Company's total revenue increased 9.5% YoY to $1.7 billion during the quarter. Net income was $7.6 million or $0.16 per diluted share in Q3 2013, compared to net income of $3.4 million or $0.07 per diluted share in Q3 2012. Commenting on the results, J. Mario Molina, M.D., CEO of Molina Healthcare, said, "I am pleased with the third quarter results, particularly because medical margins increased at all but one of our health plans. We closed on our acquisitions in New Mexico and South Carolina, welcomed our first members in Illinois and launched qualified health plans for the health insurance marketplace in nine states. While our results were tempered by the cleanup of old claims in Texas and continued administrative investments associated with future growth, I remain optimistic about our future long-term prospects." The Full Research Report on Molina Healthcare, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1a59_MOH]
Exelixis, Inc. Research Report
On October 30, 2013, Exelixis Inc. (Exelixis) reported its Q3 2013 financial results. The Company's total revenues declined 58.9% YoY to $5.5 million during the quarter. Net loss was $67.1 million or $0.36 per diluted share in Q3 2013, compared to net loss of $32.8 million or $0.20 per diluted share in Q3 2012. Michael M. Morrissey, Ph.D., President and CEO at Exelixis, said, "The continued progress of our clinical development program is illustrated by the five ongoing pivotal trials investigating cabozantinib in multiple indications, including the METEOR trial in metastatic renal cell cancer (RCC) and the CELESTIAL trial in advanced HCC. Top-line data from COMET-1 and COMET-2 and the overall survival analysis for EXAM are expected in 2014. Additionally, the phase 3 pivotal trial of vemurafenib alone or in combination with cobimetinib is also expected to report data in 2014. Thus, we believe 2014 will be an important year for Exelixis with the potential read out of a total of four phase 3 pivotal trials for the Exelixis-discovered compounds cabozantinib and cobimetinib." The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73be_EXEL]
Masimo Corporation Research Report
On October 30, 2013, Masimo Corporation (Masimo) reported its Q3 FY 2013 (period ended September 28, 2013) financial results. The Company's total revenue increased 10.4% YoY to $131.4 million during the quarter. Net income attributable to Masimo stockholders was $15.6 million or $0.27 per diluted share in Q3 FY 2013, compared to net income attributable to Masimo stockholders of $13.8 million or $0.24 per diluted share in Q3 FY 2012. Commenting on the results, Joe Kiani, Chairman and CEO of Masimo, said, "Masimo's ability to innovate technology that improves care, increases patient safety and lowers overall healthcare costs is the key success factor driving our strong third quarter results. As evidenced by our strong quarterly pulse oximetry and Pulse CO-Oximetry shipments, we are consistently expanding our customer base and, as a result, we are optimistic about our future." The Full Research Report on Masimo Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/6e22_MASI]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article